Anti-MCP1 antibody is a Human antibody of IgG class that binds to an MCP1. It developed From human combinatorial antibody library.
Figure 1 Immunoblot analysis of Akt, p70S6 kinase, and mitogen-activated protein kinase p44/p42 activation.
Representative immunoblots from four independent experiments. 1, control; 2, CCL2 (100 ng/mL, 24 h); 3, CCL2 (100 ng/mL) + C1142 (30 Ag/mL); 4, CCL2 (100 ng/mL) + CNTO888 (30 Ag/mL); 5, C1142 (30 Ag/mL); 6, CNTO888 (30 Ag/Ml).
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., ... & Pienta, K. J. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer research, 67(19), 9417-9424.
Figure 2 In vivo bioluminescent imaging of PC-3Luc cell metastasis during systemic CCL2-targeted therapy.
D to G, representative pictures illustrate images captured on day 35 from representative animals from each group: D, huIgG; E, CNTO888; F, C1322; and G, C1142.
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., ... & Pienta, K. J. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer research, 67(19), 9417-9424.
Figure 3 Anti-CCL2 antibodies in combination with docetaxel induce tumor regression in vivo.
inhibition of CCL2 in combination with docetaxel (MTD 40mg/kg) was assessed by bioluminescent imaging and quantification of total tumor burden and compared with docetaxel alone. Mice received PC-3Luc cells by intracardiac injection. Beginning on day 14, mice received PBS ( ), docetaxel + CNTO888 (.), docetaxel + C1142 (5), docetaxel + CNTO888 + C1142 ( ), or docetaxel ( w ) by i.p. injection. Docetaxel was administered every week for 3 wks (weeks 2–4), whereas antibodies were delivered twice per week for 6 wks (weeks 2–8). On week 8, all antibody treatments were stopped and tumor progression was monitored to week 12. [arrow (1), initiation of treatment; arrow (2), cessation of docetaxel; arrow (3), cessation of antibody therapy]. Statistical significance was determined at week 10between the docetaxel group and the combination docetaxel + antibody groups.
Overall significance by ANOVA revealed a significant difference between docetaxel only and docetaxel + antibody groups (P < 0.0001). Individual t tests revealed significant differences between docetaxel only and docetaxel + CNTO888 (P = 0.0003), docetaxel + C1142 (P = 0.0001), or docetaxel + C1142 + CNTO888 (P = 0.0001). Solid lines, human antibodies; dashed lines, mouse antibodies.
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., ... & Pienta, K. J. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer research, 67(19), 9417-9424.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-038 | Recombinant Anti-Human CCL2 VHH Single Domain Antibody | WB, ELISA, IHC, FuncS | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-117 | Anti-Human MCP-1 Recombinant Antibody (Carlumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
TAB-0748CL | Anti-Human CCL2 Recombinant Antibody (1.1.1) | ELISA | Human antibody |
TAB-0749CL | Anti-Human CCL2 Recombinant Antibody (1.10.1) | ELISA | Human antibody |
TAB-0750CL | Anti-Human CCL2 Recombinant Antibody (MC32) | ELISA, Block, Inhib | Human antibody |
PABX-141-F (E) | Recombinant Human Anti-MCP1 Antibody Fab Fragment (cnto888) | WB, ELISA, FuncS | Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-421 | Human Anti-CCL2 Recombinant Antibody (clone CNTO 888) | Inhib, IB, FuncS | Human IgG |
HPAB-1658-FY | Mouse Anti-CCL2 Recombinant Antibody (clone C775) | ELISA | Mouse IgG1, κ |
ZG-0153U | Mouse Anti-CCL2 Recombinant Antibody (clone 3D2E5) | ELISA, IHC | Mouse IgG2b |
VS3-WK25 | Mouse Anti-CCL2 Recombinant Antibody (clone E11-D8) | WB, ELISA | Mouse IgG1 |
VS-0923-FY32 | Recombinant Mouse Anti-CCL2 Antibody (VS-0923-FY32) | ELISA, WB | Mouse IgG2b |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-418 | Human Anti-CCL2 Recombinant Antibody (clone CNTO 888); Fab Fragment | WB, ELISA, FuncS | Human Fab |
HPAB-1658-FY-S(P) | Mouse Anti-CCL2 Recombinant Antibody (clone C775); Fab Fragment | ELISA | Mouse Fab, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-418 | Human Anti-CCL2 Recombinant Antibody (clone CNTO 888); scFv Fragment | WB, ELISA, FuncS | Human scFv |
HPAB-1658-FY-F(E) | Mouse Anti-CCL2 Recombinant Antibody (clone C775); scFv Fragment | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0744CL | Anti-Human CCL2 Recombinant Antibody (AAV293) | ELISA | |
TAB-0745CL | Anti-Human CCL2 Recombinant Antibody (AAV294) | ELISA | |
TAB-0754CL | Mouse Anti-CCL2 Recombinant Antibody (TAB-0754CL) | ELISA, SPR, DB, IHC | Mouse IgG1 |
TAB-0755CL | Mouse Anti-CCL2 Recombinant Antibody (TAB-0755CL) | SPR, DB, IHC | Mouse IgG1 |
TAB-0756CL | Mouse Anti-CCL2 Recombinant Antibody (TAB-0756CL) | ELISA, SPR, DB, IHC | Mouse IgG2b |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-147CQ | Mouse Anti-CCL2 Recombinant Antibody (clone CBL605) | WB, ELISA(Cap), ICC, Neut | Mouse IgG1 |
NEUT-161CQ | Mouse Anti-CCL2 Recombinant Antibody (clone CBL966) | ELISA, Neut, WB | Mouse IgG1, κ |
NEUT-162CQ | Rat Anti-CCL2 Recombinant Antibody (clone CBL529) | Neut | Rat IgG2b |
NEUT-163CQ | Rat Anti-CCL2 Recombinant Antibody (clone RM0172-11K27) | WB, Neut | Rat IgG2 |
NEUT-164CQ | Rat Anti-CCL2 Recombinant Antibody (clone CBL199) | Neut, WB | Rat IgG2 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0504 | Hi-Affi™ Rabbit Anti-CCL2 Recombinant Antibody (clone DS504AB) | WB, IF | Rabbit IgG |
MOR-4543 | Hi-Affi™ Rabbit Anti-CCL2 Recombinant Antibody (clone TH52DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-117 | Afuco™ Anti-CCL2 ADCC Recombinant Antibody (Carlumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
There are currently no Customer reviews or questions for PABX-141. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.